True Ventures Leads $2.5 Million Seed+ Round to Bring

True Ventures 领投 250 万美元种子轮+融资，旨在推动

Patented Handheld AI-enabled Endoscopic Robotic Platform

专利手持式人工智能内窥镜机器人平台

to Physicians

致医师

SAN DIEGO

圣迭戈

,

，

June 18, 2026

2026年6月18日

/PRNewswire/ -- Channel Robotics, a developer of a first-of-its-kind handheld endoscopic robotic platform, today announced the successful close of a

/美通社/ -- 手持式内窥镜机器人平台的首创开发商 Channel Robotics 今日宣布成功完成一轮

$2.5 million Seed+ financing round led by

由...领投的250万美元Seed+轮融资

True Ventures

True Ventures

, a leading early-stage venture capital firm known for backing transformative technology companies. The financing brings the company's

，一家领先的早期风险投资公司，以支持变革性科技公司而闻名。此次融资使该公司的

total capital raised to $4.6 million

筹集资金总额达460万美元

, supporting continued product development, regulatory advancement, and preparation for commercialization.

，支持持续的产品开发、监管推进以及商业化准备。

The Seed+ financing follows the successful close of the company's $2.1 million Seed round, which included participation from

此次Seed+轮融资紧随公司成功完成的210万美元种子轮融资，后者包括来自

Defined Ventures

Defined Ventures

and

和

Old Line Capital Partners

老线资本合伙人

. Together, these investments provide Channel with the capital and strategic support needed to advance its technology toward broader clinical adoption.

这些投资共同为Channel提供了推动其技术走向更广泛临床应用所需的资金和战略支持。

The financing syndicate brings together investors with deep expertise in healthcare, medical technology, and company building. True Ventures has a long track record of partnering with visionary founders developing transformative technologies, while Defined Ventures and Old Line Capital Partners provide specialized support for healthcare innovation and long-term company growth..

该融资银团汇聚了在医疗保健、医疗科技及企业构建方面拥有深厚专长的投资者。True Ventures 在与开发变革性技术的远见型创始人合作方面拥有悠久的良好记录，而 Defined Ventures 和 Old Line Capital Partners 则为医疗保健创新及企业的长期增长提供专业化支持。

Advancing a New Category in Endoscopic Robotics

推动内窥镜机器人新类别的发展

Channel Robotics is developing a patented handheld AI-enabled endoscopic robotic platform designed to deliver robotic-level dexterity through existing flexible endoscopes. By eliminating the need for large, capital-intensive robotic systems, the technology aims to expand access to advanced endoscopic procedures across hospitals, ambulatory surgery centers, and community practice settings..

Channel Robotics 正在开发一款获得专利的手持式人工智能内窥镜机器人平台，旨在通过现有的柔性内窥镜提供机器人级别的灵巧操作能力。该技术无需庞大且资本密集型的机器人系统，力求将先进的内窥镜手术推广至各类医院、门诊手术中心及社区医疗机构，从而扩大其可及性。

'Our mission is to democratize access to advanced endoscopic robotics,' said Michael Yip, PhD, co-founder of Channel Robotics. 'This financing enables us to continue building a platform that can bring sophisticated robotic capabilities to physicians in a practical, scalable, and cost-effective way.'.

“我们的使命是让先进内窥镜机器人技术的普及化，”Channel Robotics联合创始人Michael Yip博士表示。“这笔融资使我们能够继续打造一个平台，以实用、可扩展且具成本效益的方式，将复杂的机器人能力带给医生。”

Capital to Support Key Development and Regulatory Milestones

用于支持关键开发和监管里程碑的资金

The financing will support several critical milestones, including:

这笔融资将支持多个关键里程碑，包括：

Continued refinement and validation of the company's prototype platform

持续完善和验证公司的原型平台

Expansion of engineering and product development efforts

扩大工程和产品开发工作

Preparation for FDA submission targeted for 2027

为2027年提交FDA申请做准备

Advancement of manufacturing and quality systems

制造与质量体系的提升

Commercial launch preparation following regulatory clearance

在获得监管批准后进行商业发射准备

'Mike and Philip are a rare combination of deep clinical experience and expertise combined with robotics which enables practical solutions for an unprecedented number of clinics and physicians. Their innovation solves serious robotics challenges in service of human health, and we are honored to be a part of their journey,' Rohit Sharma, Partner at True Ventures..

“迈克和菲利普将深厚的临床经验与专业知识同机器人技术相结合，这种罕见的组合为前所未有的众多诊所和医生提供了切实可行的解决方案。他们的创新解决了服务于人类健康的重大机器人技术挑战，我们很荣幸能参与他们的征程。”True Ventures 合伙人罗希特·夏尔马表示。

'With the support of True Ventures and our existing investors, we are well-positioned to accelerate development and bring this technology to clinicians and patients,' said Philip Weissbrod, MD, co-founder and CEO of Channel Robotics. 'We believe the future of endoscopic robotics will be defined by solutions that are more accessible, easier to adopt, and capable of reaching far more patients than traditional robotic systems.'.

“在True Ventures和现有投资者的支持下，我们已蓄势待发，能够加速开发并将这项技术带给临床医生和患者。”Channel Robotics的联合创始人兼首席执行官Philip Weissbrod医学博士表示。“我们相信，内窥镜机器人的未来将由那些更易获取、更易于采用且能够惠及比传统机器人系统更多患者的解决方案所定义。”

About Channel Robotics

关于 Channel Robotics

Channel Robotics is a San Diego-based medical technology company developing a next-generation endoscopic robotic platform designed to enhance physician dexterity and expand access to advanced minimally invasive procedures. Founded by a physician-scientist Dr. Philip Weissbrod and roboticist Dr. Michael Yip, the company is focused on creating practical, scalable robotic solutions that integrate seamlessly into existing clinical workflows.

Channel Robotics 是一家总部位于圣地亚哥的医疗科技公司，致力于开发下一代内窥镜机器人平台，旨在提升医生的操作灵活性，并扩大先进微创手术的普及范围。该公司由医师兼科学家 Philip Weissbrod 博士与机器人专家 Michael Yip 博士共同创立，专注于打造实用、可扩展的机器人解决方案，使其能够无缝融入现有的临床工作流程。

Channel's technology combines novel robotic instrumentation, intuitive control systems, and artificial intelligence to enable more precise and accessible endoscopic interventions..

Channel 的技术将新型机器人器械、直观控制系统和人工智能相结合，从而实现更精准且更易普及的内镜介入治疗。

Media Contact:

媒体联系人：

Carolena Deutsch-Garcia

卡罗莱娜·多伊奇-加西亚

Channel Robotics, Inc.

频道机器人公司

[email protected]

[email protected]

www.channelrobotics.com

www.channelrobotics.com

SOURCE Channel Robotics

来源 Channel Robotics

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示